Evidence map›Paper›PMID 41250236›Full record

ArticleStem cell research & therapy2025

Production of clinical grade patient iPSC-derived 3D retinal organoids containing transplantable photoreceptor cells.

Laura R Bohrer, Luke A Wiley, Allison T Wright, Bradley Hittle, Mallory J Lang, Louisa M Affatigato, Kimerly A Powell, Lorena M Haefeli, Ian C Han, Robert F Mullins and 2 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Cell therapy for age-related macular degeneration.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  5. Review
  6. Generation of xenobiotic free retinofugal assembloids.Frontiers in cell and developmental biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Laura R BohrerInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Luke A WileyInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Allison T WrightInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Bradley HittleDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, 43210, USA.
Mallory J LangInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Louisa M AffatigatoInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Kimerly A PowellDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, 43210, USA.
Lorena M HaefeliInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Ian C HanInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Robert F MullinsInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Edwin M StoneInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA.
Budd A TuckerInstitute for Vision Research, Carver College of Medicine, University of Iowa, Iowa, IA, USA. budd-tucker@uiowa.edu.ORCID http://orcid.org/0000-0003-2178-1742

Funding

A Next Generation Outer Retinal Microphysiological SystemR01EY033331 · NEI · UNIVERSITY OF IOWA · PI MULLINS, ROBERT FOSTER, STONE, EDWIN M · 2022 to 2025
$1.5M
Label-free microfluidic isolation of patient iPSC-derived photoreceptor cellsR21EY036143 · NEI · UNIVERSITY OF IOWA · PI TUCKER, BUDD A · 2024 to 2025
$428k
National Science Foundation 2225488NEI NIH HHS EY033331NEI NIH HHS EY036143NEI NIH HHS R01 EY033331NEI NIH HHS R21 EY036143
6 · The paper itself

Abstract

backgroundNeurodegenerative conditions that affect the retina are currently the leading cause of incurable blindness in the developed world. Although gene and drug therapies are being developed to slow disease progression in some cases, restorative cell replacement approaches are needed for patients with significant vision impairment due to retinal degeneration. While a variety of different cell types have been evaluated in the context of retinal cell replacement, induced pluripotent stem cells (iPSCs), which can be generated and delivered as an autologous therapeutic, are in many ways the most attractive donor cell source currently available. Like embryonic stem cells, iPSCs must be differentiated into the target therapeutic cell type prior to transplantation. For instance, for patients with retinitis pigmentosa who have primary photoreceptor cell disease, photoreceptor cell derivation and enrichment are required prior to transplantation. Although other effective retinal differentiation protocols exist, they are often not fully compatible with clinical manufacturing.

methodsPatient-derived iPSCs were generated via Sendai viral vector mediated reprogramming of dermal fibroblasts. Retinal organoids were generated using a stepwise 3D differentiation protocol testing different current good manufacturing practice (cGMP) compliant reagents and oxygen tension in a cGMP compliant Biospherix cell culture isolator. Organoids were dissociated with papain and photoreceptor precursor cells were transplanted into immune suppressed Pde6b-null rats. Human donor cell survival, cellular identity, and synaptic integration were assessed at 3- and 30-days post-injection.

resultsWe developed of a xeno-free 3D retinal differentiation protocol based on the most robust adherent/non-adherent 3D differentiation strategies published to date. In addition, we demonstrate that while iPSC reprogramming efficiency is enhanced under reduced oxygen tension (i.e., 5%), efficient embryoid body and subsequent retinal organoid production require standard oxygen levels (i.e., 20%). Finally, we show that photoreceptor precursor cells obtained from 3D retinal organoids derived using the developed protocol under cGMP survive in the subretinal space of dystrophic Pde6b-null rats for 30 days post-transplantation and form new synaptic connections with host bipolar neurons. Importantly, synaptic connectivity between transplanted photoreceptor cells and host bipolar neurons appeared to have a positive trophic effect.

conclusionsIn this study, we report development of a xeno-free, cGMP compliant iPSC-3D retinal differentiation protocol for production of transplantable photoreceptor precursor cells.

Indexed as

Induced Pluripotent Stem CellsOrganoidsPhotoreceptor CellsPhotoreceptor Cells, VertebrateRetinaAnimalsCell DifferentiationHumansRatsAutologous photoreceptor cell replacementClinical grade 3D retinal organoidsInduced pluripotent stem cell (iPSC)Inherited retinal degenerationSubretinal transplantation

Identifiers

PMID41250236
PMCPMC12625545

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.